Haleon · 4 months ago
2026 Co-Op: Toxicology Research (6 months, July 2026 start)
USA - New Jersey - Warren
Full-time
Hybrid
New Grad
$24.50/hr - $24.50/hrHaleon is a world-leading consumer healthcare company focused on delivering better everyday health with humanity. They are seeking a Co-Op in Toxicology to assist in maintaining documentation, conducting toxicological assessments, and supporting regulatory submissions.
ConsumerHealth CareMedical
No H1B
Responsibilities
Evaluate, interpret, and summarize toxicological data on ingredients, review and edit toxicology monographs and determine/fill data gaps
Assist in contributions to various nonclinical regulatory submission documents and other scientific assessments
Organize and catalogue historical study and information files
Qualification
Required
Must be enrolled in a degree program with a major in Toxicology or related science fields
Graduating between December 2026 and May 2028
A minimum cumulative GPA of 3.0
Ability to start in July 1st, 2026
Full-time (40 hours/week) Monday-Friday 8am-4pm or 9am-5pm for 6 months
Live in NJ or provide your own funding for relocation and commuting to the office
Hybrid (mandatory 3 days in the Warren, NJ or Berkeley Heights, NJ office)
Must be eligible to work in the US at the time of, and for the duration of employment. Employees will be required to furnish evidence of US work authorization. Applicant must not require future sponsorship for an employment visa status
Creative and problem-solving thinking (solution-oriented mindset)
Strategic/big-picture thinking
Entrepreneurial and agile mindset
Strong prioritization and analytical skills
Personal accountability
Business and consumer/customer knowledge and understanding
Adaptability and resilience in ambiguity
A desire to learn and have meaningful impact
Excellent organizational skills
Leadership skills and ability to pursue each task with passion and focus
Strong communication and writing skills
Company
Haleon
Haleon is to deliver better everyday health with humanity.
Founded in 2022
10001+ employees
Funding
Current Stage
Public CompanyTotal Funding
$3.06B2025-01-16Post Ipo Secondary· $3.06B
2022-07-18IPO
Leadership Team
Brian McNamara
Chief Executive Officer
Carl Haney
Chief R&D Officer
Recent News
2026-01-11
2026-01-11
Company data provided by crunchbase